These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24038224)

  • 21. Benznidazole microcrystal preparation by solvent change precipitation and in vivo evaluation in the treatment of Chagas disease.
    Maximiano FP; de Paula LM; Figueiredo VP; de Andrade IM; Talvani A; Sá-Barreto LC; Bahia MT; Cunha-Filho MS
    Eur J Pharm Biopharm; 2011 Aug; 78(3):377-84. PubMed ID: 21397015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease?
    Seremeta KP; Arrúa EC; Okulik NB; Salomon CJ
    Colloids Surf B Biointerfaces; 2019 May; 177():169-177. PubMed ID: 30731393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.
    Molina-Morant D; Fernández ML; Bosch-Nicolau P; Sulleiro E; Bangher M; Salvador F; Sanchez-Montalva A; Ribeiro ALP; de Paula AMB; Eloi S; Correa-Oliveira R; Villar JC; Sosa-Estani S; Molina I
    Trials; 2020 Apr; 21(1):328. PubMed ID: 32293523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel solid dispersions of benznidazole: preparation, dissolution profile and biological evaluation as alternative antichagasic drug delivery system.
    Fonseca-Berzal C; Palmeiro-Roldán R; Escario JA; Torrado S; Arán VJ; Torrado-Santiago S; Gómez-Barrio A
    Exp Parasitol; 2015 Feb; 149():84-91. PubMed ID: 25583295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benznidazole Extended-Release Tablets for Improved Treatment of Chagas Disease: Preclinical Pharmacokinetic Study.
    Davanço MG; Campos ML; Rosa TA; Padilha EC; Alzate AH; Rolim LA; Rolim-Neto PJ; Peccinini RG
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2492-8. PubMed ID: 26883698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of N-benzylacetamide as a major component of human plasmatic metabolic profiling of benznidazole.
    Marson ME; Altcheh J; Moscatelli G; Moroni S; García-Bournissen F; Mastrantonio GE
    Eur J Drug Metab Pharmacokinet; 2015 Jun; 40(2):209-17. PubMed ID: 24711214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benznidazole and Chagas disease: can an old drug be the answer to an old problem?
    Mady C; Ianni BM; de Souza JL
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1427-33. PubMed ID: 18808305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: In vitro and in vivo evaluations.
    Leite DI; Fontes FV; Bastos MM; Hoelz LVB; Bianco MDCAD; de Oliveira AP; da Silva PB; da Silva CF; Batista DDGJ; da Gama ANS; Peres RB; Villar JDF; Soeiro MNC; Boechat N
    Chem Biol Drug Des; 2018 Sep; 92(3):1670-1682. PubMed ID: 29745048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an ionic-liquid-based dispersive liquid-liquid microextraction method for the determination of antichagasic drugs in human breast milk: Optimization by central composite design.
    Padró JM; Pellegrino Vidal RB; Echevarria RN; Califano AN; Reta MR
    J Sep Sci; 2015 May; 38(9):1591-600. PubMed ID: 25711461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.
    Pinazo MJ; Guerrero L; Posada E; Rodríguez E; Soy D; Gascon J
    Antimicrob Agents Chemother; 2013 Jan; 57(1):390-5. PubMed ID: 23114763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Benzonidazole: one of the rare treatment for Chagas disease].
    Coilliot C; Rouault M; Wolf A; Boulliat C; Beranger C; Gaillard K; Oliver M
    Med Trop (Mars); 2011 Feb; 71(1):25-7. PubMed ID: 21585085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-17A, a possible biomarker for the evaluation of treatment response in Trypanosoma cruzi infected children: A 12-months follow-up study in Bolivia.
    Vásquez Velásquez C; Russomando G; Espínola EE; Sanchez Z; Mochizuki K; Roca Y; Revollo J; Guzman A; Quiroga B; Rios Morgan S; Vargas Ortiz R; Zambrana Ortega A; Espinoza E; Nishizawa JE; Kamel MG; Kikuchi M; Mizukami S; Na-Bangchang K; Tien Huy N; Hirayama K
    PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007715. PubMed ID: 31553732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review.
    Arrúa EC; Seremeta KP; Bedogni GR; Okulik NB; Salomon CJ
    Acta Trop; 2019 Oct; 198():105080. PubMed ID: 31299283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of Benznidazole in Healthy Volunteers and Implications in Future Clinical Trials.
    Molina I; Salvador F; Sánchez-Montalvá A; Artaza MA; Moreno R; Perin L; Esquisabel A; Pinto L; Pedraz JL
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic Review and Meta-analysis of the Pharmacokinetics of Benznidazole in the Treatment of Chagas Disease.
    Wiens MO; Kanters S; Mills E; Peregrina Lucano AA; Gold S; Ayers D; Ferrero L; Krolewiecki A
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7035-7042. PubMed ID: 27550362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics and biodistribution of benznidazole in mice.
    Perin L; Pinto L; Balthazar Nardotto GH; da Silva Fonseca K; Oliveira Paiva B; Fernanda Rodrigues Bastos Mendes T; Molina I; Correa-Oliveira R; Melo de Abreu Vieira P; Martins Carneiro C
    J Antimicrob Chemother; 2020 Aug; 75(8):2213-2221. PubMed ID: 32356873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection.
    Rial MS; Scalise ML; López Alarcón M; Esteva MI; Búa J; Benatar AF; Prado NG; Riarte AR; Fichera LE
    Parasitology; 2019 Mar; 146(3):305-313. PubMed ID: 30301480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.